Lactobacillus reuteri Tablets Suppress Helicobacter pylori Infection

Imase, Kyoto; Tanaka, Akifumi; Tokunaga, Kazutoshi; Sugano, Hajime; Ishida, Hideyuki; Takahashi, Shinichi

doi:10.11150/kansenshogakuzasshi1970.81.387

Cited by 43 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Probiotics can prevent or inhibit the proliferation of pathogens, suppress production of virulence factors by pathogens, or modulate the immune response. L. reuteri is a promising therapy for the amelioration of infantile colic, alleviation of eczema, reduction of episodes of workplace illness, and suppression of H. pylori infection [3-9]. L. reuteri is considered an indigenous organism of the human gastrointestinal tract and is present on the mucosa of the gastric corpus, gastric antrum, duodenum, and ileum [10,11].…”

Section: Introductionmentioning

confidence: 99%

Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors

2009

View full text Add to dashboard Cite

BackgroundCommensal-derived probiotic bacteria inhibit enteric pathogens and regulate host immune responses in the gastrointestinal tract, but studies examining specific functions of beneficial microbes in the context of biofilms have been limited in scope.ResultsLactobacillus reuteri formed biofilms that retained functions potentially advantageous to the host including modulation of cytokine output and the production of the antimicrobial agent, reuterin. Immunomodulatory activities of biofilms were demonstrated by the abilities of specific L. reuteri strains to suppress human TNF production by LPS-activated monocytoid cells. Quantification of the antimicrobial glycerol derivative, reuterin, was assessed in order to document the antipathogenic potential of probiotic biofilms. L. reuteri biofilms differed in the quantities of reuterin secreted in this physiological state.ConclusionL. reuteri biofilms secreted factors that confer specific health benefits such as immunomodulation and pathogen inhibition. Future probiotic selection strategies should consider a strain's ability to perform beneficial functions as a biofilm.

show abstract

Section: Introductionmentioning

confidence: 99%

Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors

2009

View full text Add to dashboard Cite

show abstract

“…[32] Likewise other studies also showed that it definitely suppresses the growth of H. pylori in stomach and gut. [3233] L. reuteri is found naturally in humans, however, it is not found in all individuals. Therefore dietary supplementation is needed to introduce and maintain high levels of L. reuteri in some people.…”

Section: Introductionmentioning

confidence: 90%

“…In one of the studies it was found that adding reuteri to omeprazole dramatically increased the cure rate from 0% to 60% of H. pylori infected patients compared with the use of drug alone. [32] Likewise other studies also showed that it definitely suppresses the growth of H. pylori in stomach and gut. [3233] L. reuteri is found naturally in humans, however, it is not found in all individuals.…”

Section: Introductionmentioning

confidence: 92%

Helicobacter pylori in humans: Where are we now?

Hussain¹,

Salehiniya

2014

Adv Biomed Res

View full text Add to dashboard Cite

Helicobacter pylori has been associated with colonization of gastro duodenal mucosa of humans from millions of years. The main burden of the disese is in the developing countries, due to overcrowding and poor hygiene. If left untreated it leads to lot of sequlae from minor to sinister diseases over a period of time. The main challenges that remain are prevention of H. pylori-related diseases by effective treatment and screening procedures and development of a vaccine, which can address all these issues including beneficial aspects of H. pylori. The literature pertaining to different aspects of H. pylori were scrutinized from Pubmed. Material on clinical behavior, complications of chronic gastric involvement, and prevention besides role of H. pylori in nongastric diseases and the latest trends of management was collected for research and review. We continue to face many challenges. The prevention of cancer of the stomach, a worst sequlae of H. pylori continues to be a big challenge despite population screening and prevention surveys being underway in many countries. On the other hand continued scientific work has now unfolded involvement of H. pylori in extragastric diseases like cerebrovascular, cardiovascular, idiopathic thrombocytopenia, sideroblastic anemia, mental diseases, and collagen vascular diseases. In contrast, the beneficial effects of H. pylori with respect to allergic diseases and obesity are now clear. Moreover, problem of drug resistance for eradication of H. pylori has arisen for which novel treatments are being tried. Lactobacillus reuteri having anti H. pylori action is emerging as one of the promising treatment.

show abstract

“…La revisión bibliográfica se inició con la localización de una guía similar a la que pretendía-mos hacer, la Guía Clínica Canadiense para Suplementos Probióticos [7] y que permitió tener una base sobre la que formular la pregunta clínica. Para la formulación de la pregunta clínica nos hemos basado en el sistema PICO (Patient, Intervention, Comparison, Outcomes) [8]:…”

Section: Materials Y Métodosunclassified

Primera guía clínica basada en la evidencia médica para la suplementación con probióticos en la farmacia comunitaria española

Hospido¹,

Cobas²,

López³

et al. 2017

View full text Add to dashboard Cite

RESUMENSe ha elaborado la primera guía clínica española que permitirá a los farmacéuticos comunitarios y demás profesionales de la salud seleccionar, para cada indicación específica, el producto con probióti-cos adecuado, la dosis y la vía de administración. Con ello se pretende lograr que la práctica diaria de indicación farmacéutica de los suplementos probióticos esté basada en las mejores evidencias científicas disponibles. First clinical guide based on medical evidence for probiotic supplementation in Spanish community pharmacies ABSTRACTWe have developed the first Spanish clinical guide that will allow the community pharmacists and other health care professionals easily select the right product with probiotics, dosage and format for each specific indication. With the proposed guide, it is our goal that the daily pharmaceutical practice of probiotics supplementation in community pharmacy is based on the best scientific evidence available. PALABRAS CLAVEProbióticos, guía de práctica clínica, medicina basada en la evidencia, microbiota, suplementos dietéticos, farmacéutico comunitario Financiación: Ninguna. Contribución a la autoría: Todos los autores han contribuido por igual al diseño de la investigación, su desarrollo, análisis de los datos, redacción del manuscrito y revisión del contenido final. Conflicto de intereses: Ninguno. Cite este artículo como: Fernández N, Cardelle-Cobas A, Regal P, Cepeda A, Fente C. Primera guía clínica basada en la evidencia médica para la suplementación con probióticos en la farmacia comunitaria española.

show abstract

Lactobacillus reuteri Tablets Suppress Helicobacter pylori Infection

Abstract: Administration of L. reuteri Tablets [Reuterina (ERINA Co.,Inc.)] significantly decreased UBT in H. pylori-positive subjects, demonstrating that L. reuteri suppresses H. pylori urease activity and H. pylori density.

Cited by 43 publications

References 22 publications

Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors

Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors

Helicobacter pylori in humans: Where are we now?

Primera guía clínica basada en la evidencia médica para la suplementación con probióticos en la farmacia comunitaria española

Contact Info

Product

Resources

About